WO2006044107A3 - Method of treating human preeclampsia employing resibufagenin - Google Patents

Method of treating human preeclampsia employing resibufagenin Download PDF

Info

Publication number
WO2006044107A3
WO2006044107A3 PCT/US2005/034075 US2005034075W WO2006044107A3 WO 2006044107 A3 WO2006044107 A3 WO 2006044107A3 US 2005034075 W US2005034075 W US 2005034075W WO 2006044107 A3 WO2006044107 A3 WO 2006044107A3
Authority
WO
WIPO (PCT)
Prior art keywords
preeclampsia
resibufagenin
employing
treating human
blood
Prior art date
Application number
PCT/US2005/034075
Other languages
French (fr)
Other versions
WO2006044107A2 (en
Inventor
Jules B Puschett
Original Assignee
Univ Tulane
Jules B Puschett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane, Jules B Puschett filed Critical Univ Tulane
Priority to AT05802853T priority Critical patent/ATE537823T1/en
Priority to CA002584151A priority patent/CA2584151A1/en
Priority to US11/577,450 priority patent/US7759329B2/en
Priority to EP05802853A priority patent/EP1804789B1/en
Publication of WO2006044107A2 publication Critical patent/WO2006044107A2/en
Publication of WO2006044107A3 publication Critical patent/WO2006044107A3/en
Priority to US12/821,880 priority patent/US8080539B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

A method of treating preeclampsia including administering a therapeutically effective dose of resibufagenin to a patient having preeclampsia. Effecting the determination of the presence of preeclampsia may be by determining whether there has been a substantial elevation in marinobufagenin which may be blood-derived or urine-derived and if such elevation does exist, concluding that preeclampsia does exist. The method may advantageously be practiced by employing urine, blood serum or blood plasma as the body specimen containing the protein in determining whether a patient has preeclampsia. In another embodiment, bufodienolide derivatives other than resibufagenin may be employed in lieu of thereof or in combination therewith. In another embodiment, resibufagenin analogues may be employed in the treatment of preeclampsia.
PCT/US2005/034075 2004-10-19 2005-09-23 Method of treating human preeclampsia employing resibufagenin WO2006044107A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AT05802853T ATE537823T1 (en) 2004-10-19 2005-09-23 METHOD FOR TREATING PREECLAMPSIA IN HUMAN BEINGS WITH RESIBUFAGENIN
CA002584151A CA2584151A1 (en) 2004-10-19 2005-09-23 Method of treating human preeclampsia employing resibufagenin
US11/577,450 US7759329B2 (en) 2004-10-19 2005-09-23 Method of treating human preeclampsia employing resibufagenin
EP05802853A EP1804789B1 (en) 2004-10-19 2005-09-23 Method of treating human preeclampsia employing resibufagenin
US12/821,880 US8080539B2 (en) 2004-10-19 2010-06-23 Method of treating human preeclampsia employing resibufagenin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61996904P 2004-10-19 2004-10-19
US60/619,969 2004-10-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/577,450 A-371-Of-International US7612456B2 (en) 2004-08-11 2005-06-16 Electronic device, semiconductor device using same, and method for manufacturing semiconductor device
US12/821,880 Continuation US8080539B2 (en) 2004-10-19 2010-06-23 Method of treating human preeclampsia employing resibufagenin

Publications (2)

Publication Number Publication Date
WO2006044107A2 WO2006044107A2 (en) 2006-04-27
WO2006044107A3 true WO2006044107A3 (en) 2006-10-19

Family

ID=36203374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/034075 WO2006044107A2 (en) 2004-10-19 2005-09-23 Method of treating human preeclampsia employing resibufagenin

Country Status (5)

Country Link
US (2) US7759329B2 (en)
EP (1) EP1804789B1 (en)
AT (1) ATE537823T1 (en)
CA (1) CA2584151A1 (en)
WO (1) WO2006044107A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858604B2 (en) * 2005-07-12 2010-12-28 Scott & White Healthcare Method of treating human volume expansion mediated hypertension employing resibufogenin
US20110008904A1 (en) * 2009-07-10 2011-01-13 Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation Method for determining if a patient has a traumatic brain injury and related apparatus
US20110207154A1 (en) * 2010-01-12 2011-08-25 Scott & White Healthcare Method for determination of marinobufagenin levels and compounds employable in such method
RU2472506C1 (en) * 2011-11-07 2013-01-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера" Министерства здравоохранения и социального развития Российской Федерации Method for preeclampsia prevention
US20180340947A1 (en) * 2017-05-23 2018-11-29 Jules B. Puschett Involvement of the bufodienolides in the diagnosis and treatment of post-traumatic stress disorder (ptsd)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3585187A (en) * 1966-12-30 1971-06-15 Boehringer Sohn Ingelheim Novel derivatives of bufadienolide-glycosides
US5770376A (en) * 1992-12-02 1998-06-23 Biomedical Sciences Research Laboratories, Inc. Method of diagnosing and treating myocardial infarction and hypertension
US6306845B1 (en) * 1999-01-29 2001-10-23 The Trustees Of Columbia University In The City Of New York Method for treating demyelinating disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5756500A (en) * 1980-09-22 1982-04-05 Otsuka Pharmaceut Co Ltd Novel bufadienolide-type steroid
US7439071B2 (en) * 2003-02-04 2008-10-21 The Administrators Of The Tulane Educational Fund Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3585187A (en) * 1966-12-30 1971-06-15 Boehringer Sohn Ingelheim Novel derivatives of bufadienolide-glycosides
US5770376A (en) * 1992-12-02 1998-06-23 Biomedical Sciences Research Laboratories, Inc. Method of diagnosing and treating myocardial infarction and hypertension
US6306845B1 (en) * 1999-01-29 2001-10-23 The Trustees Of Columbia University In The City Of New York Method for treating demyelinating disease

Also Published As

Publication number Publication date
EP1804789A4 (en) 2010-06-23
EP1804789B1 (en) 2011-12-21
ATE537823T1 (en) 2012-01-15
US8080539B2 (en) 2011-12-20
WO2006044107A2 (en) 2006-04-27
EP1804789A2 (en) 2007-07-11
US20080261928A1 (en) 2008-10-23
US7759329B2 (en) 2010-07-20
CA2584151A1 (en) 2006-04-27
US20100305079A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
WO2007142667A3 (en) Treatment of patients with autoantibody positive disease
UA99094C2 (en) Method for the treatment of patients with autoantibody positive disease
WO2004035747A3 (en) Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
UA92348C2 (en) 17b-HSD1 AND STS INHIBITORS
WO2005107730A3 (en) Cysteamines for treating complications of hypercholesterolemia and diabetes
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
WO2003053346A3 (en) Systems and methods for treating patients with processed lipoaspirate cells
WO2006031980A3 (en) Treatment for cancer-related fatigue
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
BRPI0512503A (en) composition comprising lactic acid and lactoferrin
MXPA05010914A (en) Alzheimer's disease treatment method.
HK1064950A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
WO2003037911A3 (en) Antibodies for inhibiting blood coagulation and methods of use thereof
WO2005056585A3 (en) Sars coronavirus s proteins and uses thereof
WO2006044107A3 (en) Method of treating human preeclampsia employing resibufagenin
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2007008855A3 (en) Method of treating human volume expansion mediated hypertension employing resibufogenin
WO2004071273A3 (en) Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus
WO2007141306A3 (en) Combination of somatostatin-analogs with dopamine- or growth hormone receptor antagonist
WO2007013124A8 (en) Stimulatory auto-antibodies to the pdgf receptor as pathology marker and therapeutic target
WO2005055956A3 (en) Method for improving insulin sensitivity by administering an inhibitor of antitrypsin
BRPI0616535B8 (en) use of lipidated tissue factor (tf) or a functional fragment thereof, product, use of a product, complex (tf::fxa), use of a complex, tf::ncis complex, tf::fxa:ncis complex, pharmaceutical composition and use of non-lipidated tf or a functional fragment thereof
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin
WO2005030265A3 (en) Optical imaging of endometriosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2584151

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005802853

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005802853

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11577450

Country of ref document: US